IFNG and myalgic encephalomeyelitis/chronic fatigue syndrome: The above-mentioned evidence indicates that IFN-γ, rather than IFN-α/β, is a good biomarker in the early stage of CFS and that it can be used for clinical decisions regarding CFS severity.